Secondary Logo

Journal Logo

Ejection Fraction Improvement by β-Blocker Treatment in Patients with Heart Failure: An Analysis of Studies Published in the Literature

van Campen, Linda C. M. C.; Visser, Frans C.; Visser, Cees A.

Journal of Cardiovascular Pharmacology: 1998 - Volume 32 - Issue - p S31-S35
Treatment of Heart Failure: Current Insights and New Treatment Options
Free

Because ejection fraction (EF) is one of the most important predictors of survival in patients with left ventricular (LV) dysfunction and because Packer showed a large reduction in mortality figures with carvedilol, in contrast to former studies with bisoprolol and metoprolol, we investigated if this difference in survival may be related to a difference in improvement of LV function by different β-blockers. We searched the MEDLINE database and all reference lists of articles obtained through the search for the relation between β-blocker treatment and improvement in EF. Forty-one studies met the criteria and we added two of our own studies. Four hundred and fifty-eight patients were treated with metoprolol with a mean follow-up of 9.5 months and a mean increase in EF of 7.4 EF units. One thousand thirty patients were treated with carvedilol with a mean follow up of 7 months and a mean increase in EF of 5.7 EF units. One hundred ninety-nine patients were treated with bucindolol with a mean follow-up of 4 months and a mean increase in EF of 4.6 EF units. Several small studies with nebivolol, atenolol, and propranolol were also studied and, when combined, the mean increase in EF was 8.6 EF units. When patients with idiopathic and ischemic cardiomyopathies were compared, the average increase in EF units was 8.5 vs. 6.0, respectively. The use of β-blocker treatment in heart failure patients, irrespective of the etiology, improved LV function in almost all studies and it appears that the differences amongβ-blockers and among etiologies is small and probably insignificant. However, there is a difference in survival rate when the various β-blockers are compared, suggesting that mechanisms other than improvement of LV function by β-blockers are responsible for the difference in survival.

Department of Cardiology, Free University Hospital, Amsterdam, The Netherlands

Address correspondence and reprint requests to Dr. L. C. M. C. van Campen at Department of Cardiology, Free University Hospital, PO Box 7057, 1007 MB Amsterdam, The Netherlands.

One of the most important predictors of prognosis in patients with congestive heart failure(CHF) is the degree of left ventricular (LV) dysfunction (1-4). Since 1975 (5), substantial evidence has been published that β-blockers improve LV dysfunction in patients with CHF.

Recently, Packer et al. (6) were the first to demonstrate that carvedilol reduced the risk for mortality in CHF patients who were treated with the usual background therapy, consisting of angiotensin-converting enzyme (ACE) inhibitors, diuretics, and digoxin. In contrast, previous studies with metoprolol and bisoprolol therapy in patients with idiopathic dilated cardiomyopathy (7,8) failed to demonstrate an improvement of survival by β-blocker therapy.

One of the possible mechanisms of this difference in survival might be a different degree of improvement of LV function by the β-blockers used. Therefore, the objective of our study was to evaluate the available literature on the effect of treatment with different β-blockers on the left ventricular ejection fraction (EF) at rest in patients with CHF.

Back to Top | Article Outline

METHODS

The available literature was reviewed concerning the relation between the EF and the following β-blockers: metoprolol, carvedilol, bucindolol, atenolol, nebivolol, bisoprolol, and propranolol. The studies were identified using several combined search strategies: (a) conduction of a search from the MEDLINE database (January 1975 through June 1997) using the following key words: heart failure, β-blockers or β-adrenergic receptor blockers, and left ventricular ejection fraction; (b) using the key word combination of heart failure and ejection fraction, with the specific β-blockers as mentioned above; and (c) the reference lists of the articles obtained through the previous searches were screened for additional articles that might have been missed. Only articles in English were considered, and reviews or abstracts were discarded. Moreover, probable duplicates of patient findings by the same research group were also excluded. For inclusion in the analysis, the LVEF should have been tested by echocardiography, radionuclide ventriculography, or angiography.

Of the available studies, the etiology of LV dysfunction was noted and scored as idiopathic dilated cardiomyopathy(IDC) and/or due to coronary artery disease (CAD). Moreover, the duration of follow-up in months, the number of patients included, the baseline EF, and the EF after β-blocker therapy were noted. Finally, the degree of improvement and the statistical significance of this improvement were noted. In studies comparing β-blockers with placebo, the following procedure was applied. The baseline EF and the EF after treatment were given; the in(de)crease in EF in the placebo group was subtracted from the increase in the β-blocker group. Therefore, in these studies, ΔEF as presented in our tables may be different from the difference between EF at baseline and afterβ-blocker treatment. This approach was published previously (9).

Back to Top | Article Outline

RESULTS

Ejection increase by different β-blockers

Forty-one studies were found. Two of our studies using carvedilol in patients with LV dysfunction and hypertension were also included. The following tables show data only for patients receiving active treatment.

Table 1 shows the data for patients treated with metoprolol. Sixteen studies met our criteria. A total of 458 patients were studied. The weighted mean follow-up of the studies was 9.5 months. The weighted mean baseline EF was 24% and increased to 34%. The improvement in EF (after correction for the EF change in possible placebo groups) was 7.4 EF units, with a range of 3-16%.

TABLE 1

TABLE 1

Table 2 shows the data for patients treated with carvedilol. Fourteen studies met our criteria. A total of 1,030 patients were studied. The weighted mean follow-up of the studies was 7 months. Baseline EF was on average 24% and increased to 32% after treatment with β-blockers. After correction for possible placebo studies, the EF increased 5 EF units. The change in EF in patients with mild LV dysfunction and hypertension was similar to that of the other included studies.

TABLE 2

TABLE 2

Table 3 shows the data for patients treated with bucindolol. Seven studies met our criteria. A total of 199 patients were studied. The weighted mean follow-up of the studies was 4 months. Baseline EF was similar to studies with otherβ-blockers, 23%, and increased to 29% after treatment. The increase in EF units was on average 4.6%.

TABLE 3

TABLE 3

Table 4 shows the combined data for patients treated with atenolol, nebivolol, and propranolol. The data were pooled because of the small number of patients and because the increase in EF after treatment was similar to that observed other studies.

TABLE 4

TABLE 4

In total, 98 patients were studied, with a weighted follow-up of 13 months. Baseline EF was on average 23% and was 32% after treatment. The increase in EF units, after correction for placebo changes, was 8.6%. Figure 1 shows the weighted mean ejection fraction of the several β-blockers.

FIG. 1

FIG. 1

Back to Top | Article Outline

Idiopathic vs. ischemic cardiomyopathies

Because previous studies (10-12) have shown that with β-blocker therapy the EF increase in patients with idiopathic cardiomyopathy was larger than in patients with ischemic cardiomyopathy, we further analyzed the studies in which only patients with idiopathic or ischemic cardiomyopathy were included.

Eleven studies encompassing 361 patients with idiopathic dilated cardiomyopathy were examined. The weighted mean increase in EF units was 8.5% with a range of 3-16%.

Eleven studies were found for 269 patients with ischemic cardiomyopathy. The mean increase in EF units was 6% with a range of 3-11%. Although no statistics could be performed on the available data, the difference is obviously insignificant.

We also analyzed by linear regression if there was a positive relation between the duration of β-blocker treatment and the increase in EF. No statistical significance was found.

Back to Top | Article Outline

DISCUSSION

The current analysis shows that (a) in almost all studies a significant increase in the LVEF occurred after treatment with β-blockers, (b) differences among the variousβ-blockers used are small and probably clinically insignificant, and (c) the data suggest that there is only a small difference between patients with idiopathic vs. ischemic cardiomyopathy, which is also probably clinically insignificant.

However, this type of analysis does not allow accurate statistical comparison of the variousβ-blockers. For the latter, a meta-analysis with available data on individual patients is needed. Nevertheless, the differences in improvement are small and, importantly, mean baseline EF values for the different β-blocker studies are almost identical.

Suggested mechanisms of the beneficial effects of β-blocker treatment include blocking the adverse impact of high, possibly cardiotoxic, levels of catecholamines (13-15), and counteracting the shortened diastolic filling time, vasoconstriction by catecholamines, and reninangiotensin-aldosterone system (RAAS) activation (14-16) and increase of metabolic demand, all acting adversely on LV function in the failing heart. Moreover, β-blockers upregulate β-receptors, except for carvedilol (17). Our analysis suggests that the combined effects of these mechanisms on LV function was no different between patients with ischemic and idiopathic dilated cardiomyopathy.

Despite the same improvement in ejection fraction, studies with carvedilol (6) have shown that there is a substantial reduction in mortality. This is in contrast to the mortality studies using metoprolol and bisoprolol (7,8). This suggests that the magnitude of increase in EF by the different β-blockers is unrelated to the improved survival. Possible explanations for the beneficial effect of carvedilol include the additional effects of carvedilol and differences in sample size, as discussed by Packer et al. (6).

Additional effects of carvedilol include α1-blockade and antioxidant effects (6,18-21). In addition, the sample size of the carvedilol study was significantly larger than that of the MDC and CIBIS studies. Ongoing, large-scale, placebo-controlled multicenter mortality studies with metoprolol may provide the answer to the question of whether the specific effects of carvedilol are responsible for the mortality reduction or whether mortality reduction is a general β-blocker effect.

Back to Top | Article Outline

REFERENCES

1. Unverferth DV, Magorien R, Moeshberger M, Baker P, Fetters J, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 1984;54:147-52.
2. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 1987;59:634-8.
3.Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol 1988;62:25A-30A.
4. Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. J Am Coll Cardiol 1989;14:564-70.
5. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-36.
6. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.
7. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
8. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-6.
9. Doughty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol 1994;23:814-21.
10. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-41.
11. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993;71:12C-22C.
12. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.Circulation 1996;94:2807-16.
13. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol 1985;17:291-306.
14. Opie L. Effects of catecholamines on normal myocardium: implications for the failing heart. Heart Fail 1986;3:104-9.
15.Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
16. Michelakis AM, McAllister RG. The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J Clin Endocrinol Metab 1972;34:386-94.
17. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-25.
18. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793-9.
19. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-31.
20. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506.
21. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997;29:1060-6.
22.Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980;44:117-33.
23. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-63.
24. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-46.
25. Waagstein F, Hjalmarson A, Swedberg K, Wallentin I. Beta-blockers in dilated cardiomyopathies: they work. Eur Heart J 1983;4(suppl A):173-8.
26. Sano H, Kawabata N, Yonezawa K, Hirayama H, Sakuma I, Yasuda H. Metoprolol was more effective than captopril for dilated cardiomyopathy in Japanese patients. Circulation 1989;89(suppl II):II-118.
    27.Waagstein F, Blomstrom-Lundquist C, Andersson B, Hjalmarson A, Wallentin I. Long-term effects of metoprolol in severe heart failure due to ischemic cardiomyopathy, primary valve disease and diabetes. Circulation 1987;76(suppl IV):IV-358.
    28. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy.Circulation 1989;79:483-90.
    29. Bennett SK, Fisher ML, Krichten C, Patten RD, Greenberg NL, Gottlieb SS. Heart failure with known coronary artery disease: comparison of changes in ejection fraction with beta-blocker and placebo [Abstract]. J Am Coll Cardiol 1993;21:114A.
    30. Currie PJ, Kelly MJ, McKenzie A, et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol 1984;3:203-9.
    31. Nemanich JW, Veith RC, Abrass IB, Stratton JR. Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. Am J Cardiol 1990;66:843-8.
    32. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994;23:943-50.
    33.Heesch CM, Marcoux L, Hatfield B, Eichhorn EJ. Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure. Am J Cardiol 1995;75:360-4.
    34. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-61.
    35. Maisel AS. Beneficial effects of metoprolol treatment in congestive heart failure. Reversal of synpathetic-induced alterations of immunologic function.Circulation 1994;90:1774-80.
    36. Andersson B, Caidahl K, Waagstein F. Recovery from left ventricular asynergy in ischemic cardiomyopathy following long-term beta blockade treatment. Cardiology 1994;85:14-22.
    37. Das Gupta P, Broadhurst P, Raftery EB, Lahiri A. Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:1118-23.
    38. Metra M, Nardi M, Giubbini R, Dei CL. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-87.
    39. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-8.
    40. Krum H, Gu A, Wilshire-Clement M, et al. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J 1996;131:337-41.
    41. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996;94:2800-6.
    42. Quaife RA, Gilbert EM, Christian PE, et al. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol 1996;78:779-84.
    43. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88:223-9.
    44. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation 1994;89:1632-42.
    45.Eichhorn EJ, Heesch CM, Risser RC, Marcoux L, Hatfield B. Predictors of systolic and diastolic improvements in patients with dilated cardiomyopathy treated with metoprolol.J Am Coll Cardiol 1995;25:154-62.
    46. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990;66:603-7.
    47.Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990;82:473-83.
    48. Rousseau MF, Chapelle F, Van EC, et al. Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J Cardiac Fail 1996;2:15-23.
      49. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy.J Am Coll Cardiol 1993;21:1094-100.
      50. Erlebacher JA, Bhardwaj M, Suresh A, Leber GB, Goldweit RS. Beta-blocker treatment of idiopathic and ischemic dilated cardiomyopathy in patients with ejection fractions < or =20%.Am J Cardiol 1993;71:1467-9.

      Section Description

      Proceedings of a symposium held in Apeldoorn, The Netherlands May 31, 1997

      Keywords:

      β-Blockade; Left ventricular dysfunction; Ejection fraction; Carvedilol

      © Lippincott-Raven Publishers.